Pharma

As newly published data show the first Gamma Delta T cell therapy’s clinical efficacy in patients, the race to market for the first allogeneic and solid tumor-targeting γδT has begun. Join us at the 3rd Gamma Delta T Therapies Summit alongside 120+ of the world’s leaders in the field to discuss discovery to manufacturing and clinical development of these ‘holy grail’ therapies in allogeneic and solid tumor settings. Developed with key opinion leaders such as Adrian Hayday, and experts from Adicet Bio, Lava Therapeutics, IN8 Bio, and many more, attend this meeting to engage in interactive discussions and gain the actionable insights to advance bench to commercial bedside development of γδT-based therapies. Gather in person for the very first time with industry pioneers harnessing GDT cells to bring to market more cytotoxic, clinically safe therapies for solid tumors. From modulating cell activity through genetic engineering and antibody engagement to enhancing the functionality of GDT cells through an improved understanding of their intrinsic biology, this is a conversation you won’t want to miss.

Over the past couple of years, the engineered biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially. The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development. as the Synthetic Biology-based Therapeutics Summit) is the leading industry-defining forum made exclusively for leaders in the synthetic and engineered biology space, focusing on the technical challenges that lie ahead in the path towards commercialization.Learn from industry trailblazers at Arsenal Biosciences, bit.bio, MIT, Novome Bio, Strand Therapeutics, Synlogic and more, to support your efforts in developing safe and effective synthetic biology-based therapeutics.  

A two-day London event with the leading expertise on innovative formulation strategies and technologies, as well as the research improving the delivery of complex therapeutics. 2 events in one: 9th Annual Formulation & Drug Delivery Congress and 8th Annual Inhalation & Respiratory Drug Delivery Congress

Exploring the latest developments & research across biologics and small molecule formulation & drug delivery, new modalities formulation & delivery as well inhaled drug delivery. 2 events in one: 5th Annual Formulation & Drug Delivery USA Congress;
5th Annual Inhalation & Respiratory Drug Delivery USA Congress

Recognised with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms. The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects and enabling efficient tissue-specific delivery to help you progress your program into and through the clinic.

From the earliest stages of characterization to the final steps of preparing for release and commercialization, our diverse program provides a comprehensive and unparalleled journey through end-to-end potency assay considerations. With a focus on practical insights, this summit equips you with the knowledge and expertise to ensure you’re prepared to excel in your role, which ultimately will bring better therapies to patients faster.

The Cell Therapy Analytical Development Summit Europe is the leading industry-defining forum in Europe made exclusively for analytical, CMC, QC, process development and regulatory experts. Next generation cell therapies are emerging as game changing treatments for cancer and beyond, but given their increasing complexities, developing robust, reliable, and in-depth analytical assays is critical to prove their safety and quality to the regulatory authorities.

New for 2022, take advantage of two tracks of content showcasing; Pre-IND & Early Clinical Development Exploring Assay Development for Best-in-Class Early-Stage Characterization; Establishing the Safety of Cell Therapy Products with Comprehensive Analytics Starting with the End-in-Mind: Considerations for Raw & Starting Material Analysis Optimizing Early-Stage Analytics to Bolster Speed to IND Submission & Phase 1 Launch Clinical Development & Commercialization; Improving Method Validation to Prepare for Successful Clinical Production; Approaching Later-Stage Analytical & Process Technology Transfers; Scaling Up from Clinical Development to Commercialization & Preparing for Release Optimizing Analytics During Manufacturing, Dealing with Process Changes

Join the CAR-TCR Summit Europe to connect with those trailblazing the next wave of CAR and TCR based approaches from preclinical development with in vivo engineering and regulatory fast-track strategies to streamlined analytics and automation to make CAR and TCR therapies better, and faster. Take advantage of cutting-edge innovation from global biopharma leaders in cell armouring, combination approaches and multiplexing gene engineering to improve cell durability and trafficking across allogeneic and solid tumor indications, and leave understanding the technical strategies to build automated, closed-system manufacturing processes to ensure vein to vein time is less than a week. Promising data-driven case studies outlining next generation product design, clinical trial set-up and manufacturing processes, this meeting is your go-to to comprehensively assess the emerging improvements of CAR and TCR based therapies across all emerging cell types including T, NK, macrophage, gamma delta T and iPSC.

After the explosive news that CAR-T therapies can now be considered curative, now is the time to unite with your industry, from the long-standing commercial giants to the trailblazing pioneers, and discover new strategies for everything from discovery to early phase development to commercialization. Gain end-to-end insights from both established thought leaders and the innovators bringing disruptive technologies from bench to bedside and from vein to vein. Across 3 conference days with 8 tracks, 13 Workshops, 1 Bootcamp and 1 Focus Day, 200+ CAR and TCR experts will lead you and 1,000 of your peers in discussions that will accelerate your pipeline and bring much-needed treatments to patients faster.